drugset / Trial / NCT05378672

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

NCT05378672

Phase 3 Completed 8 enrolled Zealand Pharma Novo Nordisk A/S · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use. In addition, the study will investigate how dasiglucagon works in the body (pharmacokinetics and pharmacodynamics). Participants will receive 1 single dose as an injection under the skin (subcutaneous, s.c.) into the buttocks. Participants will have 3 visits with the study team. For each participant, the study will last up to 84 days.

Timeline

Start
2023-05-09
Primary completion
2024-10-29
Completion
2024-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasiglucagon Peptide 0.3 mg Subcutaneous
Subject Dasiglucagon Peptide 0.6 mg Subcutaneous